Search

everythinglearnresearchcommunity

for

Search:↓

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

The user is frustrated with their dermatologist's refusal to prescribe oral Minoxidil and Finasteride for hair loss, despite starting Finasteride recently. They consider discussing oral Minoxidil with their primary care doctor and exploring telehealth options.

The user has been using finasteride for 6 months and recently added topical minoxidil and finasteride. They are seeking advice on whether to expect full recovery and are considering long-term maintenance with these treatments.

The conversation is about a person recovering from drug-induced malnourishment, regaining hair growth, and improving overall health. They attribute their progress to stopping drug use, focusing on nutrition, and possibly using hormone replacement therapy (HRT).

Hair loss discussion includes microneedling and optimal needle lengths. Users suggest doing treatments at night for better healing.

Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.

The user is experiencing scalp itching despite using finasteride and Ketoconazole shampoo for hair loss and seborrheic dermatitis. They are unsure if the itch is due to their treatments, diet, or mental factors.

A user previously claimed to take 40mg of dutasteride daily and planned to try Cyclosporine, but their account and comments have since been deleted, raising concerns about their well-being. Other users discussed the risks and effectiveness of high doses of dutasteride, with some sharing their own experiences using dutasteride, finasteride, and minoxidil for hair loss treatment.

A user shared their 7-month progress using only topical finasteride for hair loss. They recently started a new, non-FDA treatment and will evaluate its effectiveness in 6 months.

The user has seen positive results after 16 months of using topical Finasteride/Minoxidil, microneedling weekly, and Tretinoin for hair loss. There are no reported side effects, and the user advises that the effectiveness of microneedling depends on the pressure applied.

The user is experiencing one-sided diffuse thinning and has been using finasteride and liquid minoxidil for 4-5 years with minimal results. They are considering whether to save for a hair transplant or address scalp sensitivity and irritation first.

The potential risks of long-term use of Dutasteride and how it may be linked to elevated liver enzymes, cholesterol levels, and decreased testosterone. Alternative treatments such as Finasteride and RU58841 were also discussed.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

The user experienced bladder and prostate discomfort after taking finasteride and stopped the medication, but symptoms returned upon resuming at a lower dose. The doctor suggested trying dutasteride as an alternative.

The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.